CORRECTING and REPLACING The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)

CORRECTION...by Law Offices of Howard G. Smith

BENSALEM, Pa.--()--First paragraph, first sentence of release dated October 16, 2018, should read: Law Offices of Howard G. Smith reminds investors of the November 20, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) securities between October 25, 2013 and September 18, 2018, inclusive (the “Class Period”) (instead of Law Offices of Howard G. Smith reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) securities between October 25, 2013 and September 18, 2018, inclusive (the “Class Period”)).

The corrected release reads:

THE LAW OFFICES OF HOWARD G. SMITH REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST ABBVIE INC. (ABBV)

Law Offices of Howard G. Smith reminds investors of the November 20, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) securities between October 25, 2013 and September 18, 2018, inclusive (the “Class Period”). AbbVie investors have until November 20, 2018 to file a lead plaintiff motion.

Investors suffering losses on their AbbVie investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On September 18, 2018, California insurance regulators announced that they were suing AbbVie, alleging that the Company provided illegal kickbacks to health care providers while promoting Humira. On this news, AbbVie’s share price fell $2.76 per share, or almost 3%, to close at $92.61 per share on September 18, 2018, thereby injuring investors.

The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie's strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

If you purchased shares of AbbVie during the Class Period you may move the Court no later than November 20, 2018 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Release Summary

The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)

$Cashtags

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com